Evidence map›Paper›PMID 37941145›Full record

ArticleNucleic acids research2023

Improving the RNA velocity approach with single-cell RNA lifecycle (nascent, mature and degrading RNAs) sequencing technologies.

Chen Zhang, Yitong Fang, Weitian Chen, Zhichao Chen, Ying Zhang, Yeming Xie, Wenfang Chen, Zhe Xie, Mei Guo, Juan Wang and 3 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Advances in single-cell long-read sequencing technologies.NAR genomics and bioinformatics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chen ZhangBGI, Shenzhen 518000, China.
Yitong FangBGI, Shenzhen 518000, China.
Weitian ChenBGI, Shenzhen 518000, China.
Zhichao ChenBGI, Shenzhen 518000, China.
Ying ZhangGuangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital), Guangzhou, China; NHC Key Laboratory of Male Reproduction and Genetics, Guangzhou, China.
Yeming XieBGI, Shenzhen 518000, China.
Wenfang ChenBGI, Shenzhen 518000, China.
Zhe XieBGI, Shenzhen 518000, China.
Mei GuoBGI, Shenzhen 518000, China.
Juan WangBGI, Shenzhen 518000, China.
Chen TanBGI, Shenzhen 518000, China.
Hongqi WangBGI, Shenzhen 518000, China.
Chong TangBGI, Shenzhen 518000, China.ORCID 0000-0002-6898-8946

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We presented an experimental method called FLOUR-seq, which combines BD Rhapsody and nanopore sequencing to detect the RNA lifecycle (including nascent, mature, and degrading RNAs) in cells. Additionally, we updated our HIT-scISOseq V2 to discover a more accurate RNA lifecycle using 10x Chromium and Pacbio sequencing. Most importantly, to explore how single-cell full-length RNA sequencing technologies could help improve the RNA velocity approach, we introduced a new algorithm called 'Region Velocity' to more accurately configure cellular RNA velocity. We applied this algorithm to study spermiogenesis and compared the performance of FLOUR-seq with Pacbio-based HIT-scISOseq V2. Our findings demonstrated that 'Region Velocity' is more suitable for analyzing single-cell full-length RNA data than traditional RNA velocity approaches. These novel methods could be useful for researchers looking to discover full-length RNAs in single cells and comprehensively monitor RNA lifecycle in cells.

Indexed as

Nanopore SequencingSequence Analysis, RNASingle-Cell AnalysisAlgorithmsHigh-Throughput Nucleotide Sequencing

Identifiers

PMID37941145
PMCPMC10711548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.